These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 30692991)
41. Targeting Natural Killer Cells for Improved Immunity and Control of the Adaptive Immune Response. Pierce S; Geanes ES; Bradley T Front Cell Infect Microbiol; 2020; 10():231. PubMed ID: 32509600 [TBL] [Abstract][Full Text] [Related]
42. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Chester C; Marabelle A; Houot R; Kohrt HE Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932 [TBL] [Abstract][Full Text] [Related]
43. Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy. Hussain M; Shah Z; Abbas N; Javeed A; Mukhtar MM; Zhang J Med Hypotheses; 2016 Jan; 86():56-9. PubMed ID: 26804598 [TBL] [Abstract][Full Text] [Related]
44. Radiation and immunotherapy: a synergistic combination. Kalbasi A; June CH; Haas N; Vapiwala N J Clin Invest; 2013 Jul; 123(7):2756-63. PubMed ID: 23863633 [TBL] [Abstract][Full Text] [Related]
45. Cancer vaccination at older age. Gravekamp C Interdiscip Top Gerontol; 2013; 38():28-37. PubMed ID: 23503513 [TBL] [Abstract][Full Text] [Related]
47. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. Park SY; Kim IS Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590 [TBL] [Abstract][Full Text] [Related]
48. Adaptive Immunity and the Tumor Microenvironment. Han ; Lotze Cancer Treat Res; 2020; 180():111-147. PubMed ID: 32215868 [TBL] [Abstract][Full Text] [Related]
49. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172 [TBL] [Abstract][Full Text] [Related]
50. NK cells interactions with dendritic cells shape innate and adaptive immunity. Brilot F; Strowig T; Munz C Front Biosci; 2008 May; 13():6443-54. PubMed ID: 18508671 [TBL] [Abstract][Full Text] [Related]
51. Born to Kill: NK Cells Go to War against Cancer. Wennerberg E; Galluzzi L Trends Cancer; 2019 Mar; 5(3):143-145. PubMed ID: 30898260 [TBL] [Abstract][Full Text] [Related]
52. The cells that mediate innate immune memory and their functional significance in inflammatory and infectious diseases. Gardiner CM; Mills KH Semin Immunol; 2016 Aug; 28(4):343-50. PubMed ID: 26979658 [TBL] [Abstract][Full Text] [Related]
57. Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches. Gómez V; Mustapha R; Ng K; Ng T Br J Clin Pharmacol; 2020 Sep; 86(9):1726-1735. PubMed ID: 32388875 [TBL] [Abstract][Full Text] [Related]
58. Long-term treatment with a health product (Squina Diacylglyceryl Ether) enhances innate and adaptive immunity in mice. Leung HY; Ko KM J Complement Integr Med; 2012 Nov; 9():. PubMed ID: 23192054 [TBL] [Abstract][Full Text] [Related]
59. Effect of tumor cells and tumor microenvironment on NK-cell function. Vitale M; Cantoni C; Pietra G; Mingari MC; Moretta L Eur J Immunol; 2014 Jun; 44(6):1582-92. PubMed ID: 24777896 [TBL] [Abstract][Full Text] [Related]
60. Mast cells as targets for immunotherapy of solid tumors. Oldford SA; Marshall JS Mol Immunol; 2015 Jan; 63(1):113-24. PubMed ID: 24698842 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]